Latest Als News

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Paterson Resources has secured heritage clearance and reported promising metallurgical results at its Grace Gold-Copper Project, setting the stage for a significant drilling campaign to upgrade its resource estimate.

Tivan Limited has identified three new copper mineralisation sites at its Turiscai Project in Timor-Leste, advancing its early-stage exploration with assay results expected in September 2025.

icetana Limited reports its strongest quarterly annual recurring revenue growth in over four years, boosted by a landmark $3.6 million strategic partnership with SoftBank Robotics Group and expanding global deployments.

Ordell Minerals reports outstanding metallurgical test results from its McNabs East Prospect, demonstrating potential gold recoveries exceeding 95% via conventional processing methods. These findings significantly de-risk the Barimaia Gold Project ahead of a maiden resource estimate expected later this year.

QMines Limited reports promising open pit optimisation results for its newly acquired Mount Mackenzie gold-silver project, reinforcing its strategy to develop a regional processing hub in Queensland.

Solis Minerals has intersected visible copper and gold mineralisation in its second diamond drill hole at the Chancho al Palo project in Peru, reinforcing the potential for a significant copper-gold system. Assay results are expected in July/August 2025.

Lode Resources has received initial tin assay results from its ongoing drilling at the Montezuma Antimony & Silver Project, significantly enhancing previously reported high-grade intercepts and underscoring the polymetallic nature of the deposit.

Cobre Limited has initiated an Environmental Impact Assessment and reported strong assay results from its Ngami Copper Project, setting the stage for a maiden Mineral Resource Estimate by August 2025.

Lode Resources has received initial gold assay results that significantly enhance the high-grade antimony and silver intercepts at its Montezuma Project in Tasmania, underscoring the deposit’s growing critical minerals profile.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Tivan Limited has visually confirmed copper mineralisation at two sites within its Turiscai Project in Timor-Leste, setting the stage for assay results later this year and resource drilling in 2026.